semaj83/ctmatch_classification huggingface dataset:
Patient description: The patient is a 60-year-old woman admitted to the stroke department with a recent history of a second course of intravenous antibiotics for aspiration pneumonia. She is febrile and complained of abdominal pain and diarrhea (bowel movements eight times in 3 hours, large volumes of greenish, liquid stool each time). The patient's abdomen is generally tender and distend with hyperactive bowel sounds. She is febrile (38.4°C), tachycardic (113/min) and hypotensive (80/40 mmHg). The stool samples must were positive for Clostridium difficile toxin.

Clinical trial eligibility criteria: eligible ages (years): 1.0-30.0,  Down Syndrome Recurrent B Acute Lymphoblastic Leukemia Patients must be >= 1 and < 31 years at time of enrollment Patients must have first relapse of CD19+ B-ALL (relapse blasts must express CD19) in one of the following categories Isolated bone marrow relapse Isolated central nervous system (CNS) (excluding known optic nerve/retinal and CNS chloromas) and/or testicular relapse Combined bone marrow with extramedullary relapse in the CNS (excluding known optic nerve/retinal and CNS chloromas) and/or testes Patients with Down syndrome (DS) are eligible in the following categories Isolated bone marrow relapse Combined bone marrow with CNS (excluding known optic nerve/retinal and CNS chloromas) and/or testicular relapse Patients must have a performance status corresponding to Eastern Cooperative Oncology Group (ECOG) scores of 0, 1 or 2. Use Karnofsky for patients > 16 years of age and Lansky for patients =< 16 years of age Patients must have fully recovered from the acute toxic effects of all prior chemotherapy, immunotherapy, or radiotherapy prior to entering this study  Patients with B-lymphoblastic lymphoma (B-LLy) Patients with Burkitt leukemia/lymphoma or mature B-cell leukemia Patients with Philadelphia chromosome positive (Ph+) B-ALL Patients with mixed phenotype acute leukemia (MPAL) Patients with known Charcot-Marie-Tooth disease Patients with known MYC translocation associated with mature (Burkitt) B-cell ALL, regardless of blast immunophenotype Patients with active, uncontrolled infection defined as Positive bacterial blood culture within 48 hours of study enrollment Receiving IV or PO antibiotics for an infection with continued signs or symptoms. Note: Patients may be receiving IV or oral antibiotics to complete a course of therapy for a prior documented infection as long as cultures have been negative for at least 48 hours and signs or symptoms of active infection have resolved. For patients with clostridium (C.) difficile diarrhea, at least 72 hours of antibacterial therapy must have elapsed and stools must have normalized to baseline Fever above 38.2 degrees Celsius (C) within 48 hours of study enrollment with clinical signs of infection. Fever without clinical signs of infection that is attributed to tumor burden is allowed as long as blood cultures are negative for > 48 hours
Patient description: The patient is a 60-year-old woman admitted to the stroke department with a recent history of a second course of intravenous antibiotics for aspiration pneumonia. She is febrile and complained of abdominal pain and diarrhea (bowel movements eight times in 3 hours, large volumes of greenish, liquid stool each time). The patient's abdomen is generally tender and distend with hyperactive bowel sounds. She is febrile (38.4°C), tachycardic (113/min) and hypotensive (80/40 mmHg). The stool samples must were positive for Clostridium difficile toxin.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Solid Tumor Patients starting dual immune checkpoint inhibitor therapy (ipilimumab and nivolumab in any dose combination) for solid cancer treatment Ability to understand and the willingness to sign a written informed consent  Patients with a history of colectomy and/or gastric bypass Patients with a known diagnosis of inflammatory bowel disease or irritable bowel syndrome Patients with active Clostridium difficile infection. Active infection is defined as a stool sample positive for Clostridium difficile toxin by EIA and either symptoms (frequent loose stools) OR imaging findings consistent with toxic megacolon Inability to take oral supplements Patients with existing gastrointestinal symptoms including abdominal pain, diarrhea (watery stool), nausea and/or actively requiring regular anti-emetics Patients with symptomatic bowel metastasis including pain, severe constipation, or gastrointestinal bleeding Receiving antibiotic within 14 days of ICI therapy initiation Any physical or psychological condition that, in the opinion of the investigator, would pose unacceptable risk to the patient or raise concern that the patient would not comply with protocol procedures
Patient description: The patient is a 60-year-old woman admitted to the stroke department with a recent history of a second course of intravenous antibiotics for aspiration pneumonia. She is febrile and complained of abdominal pain and diarrhea (bowel movements eight times in 3 hours, large volumes of greenish, liquid stool each time). The patient's abdomen is generally tender and distend with hyperactive bowel sounds. She is febrile (38.4°C), tachycardic (113/min) and hypotensive (80/40 mmHg). The stool samples must were positive for Clostridium difficile toxin.

Clinical trial eligibility criteria: eligible ages (years): 18.0-75.0,  Irritable Bowel Syndrome With Diarrhea Male or female subjects aged 18-75 years old inclusive Onset of clinical symptoms for IBS-D occurring at least 6 months and, in order to progress to treatment phase, meet the following: 1. Has abdominal pain, on average, ≥1 day per week in previous 3 months, associated with ≥2 of the following: (1) Related to defecation, (2) Associated with a change in stool frequency, or (3) Associated with a change in form (appearance) of stool. 2. Fits Rome IV for IBS with diarrhea (IBS-D), which is defined by >25% of abnormal bowel movements with Bristol stool form types 6 or 7 (loose, watery stool) and <25% of abnormal bowel movements with Bristol stool form types 1 or 2 (hard, lumpy stool) Colonoscopy must have been completed within the past 10 years Subjects are capable of understanding the requirements of the study, are willing to comply with all the study procedures, and are willing to attend all study visits All subjects (male and female) shall agree to use an acceptable method of contraception throughout their participation in the study. Acceptable methods of contraception 1. Double barrier methods (condom with spermicidal jelly or a diaphragm with spermicide), 2. Hormonal methods (e. g. oral contraceptives, patches or medroxyprogesterone acetate), 3. An intrauterine device (IUD) with a documented failure rate of less than 1% per year. 4. Abstinence or partner(s) with a vasectomy may be considered an acceptable method of contraception at the discretion of the investigator. 5. Female subjects who have been surgically sterilized (e.g. hysterectomy or bilateral tubal ligation) or who are postmenopausal (total cessation of menses for >1 year) will not be considered "females of childbearing potential"  Use of any oral antibiotics in the last two months Subjects with history of intestinal surgery (except appendectomy or cholecystectomy) Subjects with known pelvic floor dysfunction Pregnancy Nursing mothers Poorly controlled/uncontrolled significant medical condition that would interfere with study procedures History of bowel obstruction History of inflammatory bowel disease or celiac disease History of HIV Cirrhosis
Patient description: The patient is a 60-year-old woman admitted to the stroke department with a recent history of a second course of intravenous antibiotics for aspiration pneumonia. She is febrile and complained of abdominal pain and diarrhea (bowel movements eight times in 3 hours, large volumes of greenish, liquid stool each time). The patient's abdomen is generally tender and distend with hyperactive bowel sounds. She is febrile (38.4°C), tachycardic (113/min) and hypotensive (80/40 mmHg). The stool samples must were positive for Clostridium difficile toxin.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Covid19 Pregnancy Complications Premature Rupture of Membrane Abruptio Placentae Prelabor Rupture of Membranes Stillbirth - Patients eligible for follow-up o target population will be any pregnant woman who is suspected or needs to be ruled out as having a SARS-CoV-2 infection at any time during pregnancy with positive test results for SARS-CoV-2 by PCR. Information regarding each pregnant woman's demographic characteristics, comorbidities and current obstetric history was extracted from the medical history and the patient interview; subsequently, age and race were categorized according to the classification used by the Center for Disease Control and Prevention (CDC) (17). For the selection of the control group to be collected in the same database, patients with a negative COVID-19 delivery diagnosed by PCR screening at delivery, or less than 3 days before, were considered  Pregnant women under the following conditions will be excluded from the registry Inability to give informed consent in the absence of a legal representative If, in the opinion of the researcher, findings in the physical examination, anomalies in the results of the laboratory tests or other medical, social or psychosocial factors could have a negative influence Loss of follow-up data prior to 6 weeks postpartum
Patient description: The patient is a 60-year-old woman admitted to the stroke department with a recent history of a second course of intravenous antibiotics for aspiration pneumonia. She is febrile and complained of abdominal pain and diarrhea (bowel movements eight times in 3 hours, large volumes of greenish, liquid stool each time). The patient's abdomen is generally tender and distend with hyperactive bowel sounds. She is febrile (38.4°C), tachycardic (113/min) and hypotensive (80/40 mmHg). The stool samples must were positive for Clostridium difficile toxin.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Vaginal Laceration During Delivery years old and older d or 4th degree laceration upon delivering vaginally at Prentice Women's Hospital English-speaking Administered Ancef during wound repair First Delivery Single child being born Term Delivery (i.e. at least 37 weeks gestation)  Under 18 years old Non-English speaking Delivery of more than one fetus (i.e. twins or other multiples) Patient is taking systemic steroids Allergy to Amoxicillin AND Clindamycin History of C. Difficile infection Infant with severe jaundice who is receiving breastmilk Women who have medical contraindications to the use of metronidazole, clindamycin, and amoxicillin clavulanate
Patient description: The patient is a 60-year-old woman admitted to the stroke department with a recent history of a second course of intravenous antibiotics for aspiration pneumonia. She is febrile and complained of abdominal pain and diarrhea (bowel movements eight times in 3 hours, large volumes of greenish, liquid stool each time). The patient's abdomen is generally tender and distend with hyperactive bowel sounds. She is febrile (38.4°C), tachycardic (113/min) and hypotensive (80/40 mmHg). The stool samples must were positive for Clostridium difficile toxin.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Colorectal Cancer age ≥18 years able to provide written informed consent  hypersensitivity to iodine-containing compounds pregnant or lactating diuretic therapy, and enrollment in other clinical research trials involving investigational drugs
Patient description: The patient is a 60-year-old woman admitted to the stroke department with a recent history of a second course of intravenous antibiotics for aspiration pneumonia. She is febrile and complained of abdominal pain and diarrhea (bowel movements eight times in 3 hours, large volumes of greenish, liquid stool each time). The patient's abdomen is generally tender and distend with hyperactive bowel sounds. She is febrile (38.4°C), tachycardic (113/min) and hypotensive (80/40 mmHg). The stool samples must were positive for Clostridium difficile toxin.

Clinical trial eligibility criteria: eligible ages (years): 18.0-55.0,  Non-Alcoholic Fatty Liver Disease Patients posted for Upper GI endoscopy for other indications 2. 18 yrs of age with NAFLD and 3. BMI ≤ 35 or 4. Body Mass Index (BMI) is ≤30 to 34.9 kg/m2 with at least one treated or untreated comorbid condition (hypertension, dyslipidaemia, cardiovascular disease, glucose intolerance, sleep apnoea, NASH). 5. Ambulatory and able to perform the ILBS healthy lifestyle (diet and exercise program). 6. Failed to life style therapy  HIV, HBsAg or HCV positive 2. Prior bariatric surgery 3. Change in weight of ≤5 % within 3 months 4. Malignancy within 5 years 5. Recent major surgery; history of seizure disorder 6. Depression or other major psychiatric disease within 2 years requiring treatment with prescription medication 7. Pregnancy or lactation 8. Significant uncontrolled cardiopulmonary diseases 9. Major surgical procedure (intrathoracic, intracranial, intraperitoneal, liposuction) within 6 months of screening 10. Hypo or hyperthyroidism uncontrolled. If initiation or adjustment of doses of these drugs is anticipated, patients should not be enrolled. 11. Patients being treated for hypothyroidism must be adequately replaced on a stable dose of medication for at least 3 months prior to screening. 12. Uncontrolled DM with HbA1c greater than 9%. 13. Recent treatment (i.e., within 1 month of the screening visit) with weight drugs or products or appetite suppressants (including herbal weight agents) 14. Recent treatment (i.e., within 3 months of the screening visit) with oral or parenteral corticosteroids 15. Recent history (within 2 years prior to the screening visit) of significant alcohol use 16. Significant change in diet or level of physical activity within 1 month prior to enrolment 17. Use of very-low calorie (< 1,000/day) liquid weight diet within 6 months
Patient description: The patient is a 60-year-old woman admitted to the stroke department with a recent history of a second course of intravenous antibiotics for aspiration pneumonia. She is febrile and complained of abdominal pain and diarrhea (bowel movements eight times in 3 hours, large volumes of greenish, liquid stool each time). The patient's abdomen is generally tender and distend with hyperactive bowel sounds. She is febrile (38.4°C), tachycardic (113/min) and hypotensive (80/40 mmHg). The stool samples must were positive for Clostridium difficile toxin.

Clinical trial eligibility criteria: eligible ages (years): 18.0-90.0,  Nutritional Support, Catheterization, Post-pyloric Feeding Tube, Dysphagia All patients had dysphagia that could not be alleviated within 48 hours High-risk status with aspiration pneumonia, including consciousness disorder caused by various diseases, severe dementia, bed rest, gastroesophageal reflux, hiccup, gastric retention, achalasia of pyloric Can't receive nasogastric tube feeding  The previous history of upper abdominal surgery Gastroduodenal ulcer and esophagogastric varices Severe sinusitis and nasal bone fracture Patients with recent gastrointestinal bleeding, intestinal obstruction, ischemic bowel disease, and epistaxis Patients with electromagnetically-guided catheterization should additionally implantable cardiac defibrillator, implantable cardiac pacemaker or diaphragm pacemaker
Patient description: The patient is a 60-year-old woman admitted to the stroke department with a recent history of a second course of intravenous antibiotics for aspiration pneumonia. She is febrile and complained of abdominal pain and diarrhea (bowel movements eight times in 3 hours, large volumes of greenish, liquid stool each time). The patient's abdomen is generally tender and distend with hyperactive bowel sounds. She is febrile (38.4°C), tachycardic (113/min) and hypotensive (80/40 mmHg). The stool samples must were positive for Clostridium difficile toxin.

Clinical trial eligibility criteria: eligible ages (years): 45.0-85.0,  Sepsis Community-acquired Pneumonia Organ Dysfunction Syndrome Male or female ≥45 years and ≤85 years of age Suspected, presumed or documented community-acquired pneumonia by imaging Treatment with antibiotics after at least one course for the suspected infection Meets Sepsis 3 the presence of organ dysfunction as identified by a total SOFA score ≥2 points above pre-admission SOFA Has at least one respiratory SOFA score and at least one additional SOFA in any other organ Signed written informed consent by the patient, or his/her legal guardian or delayed patient consent (based on MOH guidelines and local Ethics Committee (EC) approval) Child-bearing potential Females must not be lactating or pregnant at Screening, as documented by a negative Beta-Human Chorionic Gonadotropin (ß-hCG) or Human Chorionic Gonadotropin (hCG) blood test Women of child-bearing potential or males whose partners are women of child-bearing potential, use an effective method of contraception throughout the trial  Sepsis due to infection other than lung infection, or sepsis patients where site of infection is unclear or unknown On chronic dialysis Invasive ventilated patient with PaO2/FiO2 < 100 mmHg Weight <50 kg or >120 kg or Body Mass Index (BMI) >40 kg/m2 SOFA score ≥ 10 at screening (Day -1) Septic shock defined by persisting hypotension requiring vasopressors to maintain MAP ≥65 mmHg and having a serum lactate level >2 mmol/L (18 mg/dL) despite adequate volume resuscitation at screening and on Day 1 prior to IP administration Surgical intervention, plan for surgical intervention (not including percutaneous procedure such as chest drain), or hospitalization within 30 days prior to diagnosis of sepsis A known malignancy that is progressing or has required active treatment within the past 3 months Patient with end-stage disease (unrelated to sepsis) defined as patients who prior to the current hospitalization are expected to live < 6 months (as assessed by the study physician) Known active severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) or chronic viral infections, such as, Hepatitis B Virus (HBV) or Hepatitis C Virus (HCV), Human Immunodeficiency Virus (HIV) or other chronic infections
Patient description: The patient is a 60-year-old woman admitted to the stroke department with a recent history of a second course of intravenous antibiotics for aspiration pneumonia. She is febrile and complained of abdominal pain and diarrhea (bowel movements eight times in 3 hours, large volumes of greenish, liquid stool each time). The patient's abdomen is generally tender and distend with hyperactive bowel sounds. She is febrile (38.4°C), tachycardic (113/min) and hypotensive (80/40 mmHg). The stool samples must were positive for Clostridium difficile toxin.

Clinical trial eligibility criteria: eligible ages (years): 18.0-70.0,  Irritable Bowel Syndrome Diagnosis of irritable bowel syndrome (IBS) with predominant constipation (IBS-C) or IBS with predominant diarrhea (IBS-D) according to Rome IV at Screening Body mass index (BMI) 18.0 to 40.0 kilograms per square meter (kg/m^2), inclusive at Screening Negative test results for alcohol and selected drugs at Screening and Day 1 Negative hepatitis panel (including hepatitis B surface antigen [HBsAg] and hepatitis C virus antibody [anti-HCV]) and negative for human immunodeficiency virus (HIV) antibody screens at Screening Participants with recent (within 6 months of Screening) or ongoing alarm features (unexplained weight loss, nocturnal symptoms, blood mixed with stool) are to have had a diagnostic colonoscopy prior to Screening and after the onset of alarm features (for participants with alarm features) to non-IBS conditions per the Rome IV diagnostic algorithm for IBS  Pregnant or lactating Structural or metabolic diseases/conditions that affect the gastrointestinal system Diagnosis of IBS with mixed bowel habits (IBS-M) or unsubtyped IBS (IBS-U) Unable to withdraw medications that alter gastrointestinal (GI) transit for 72 hours prior to baseline colonic transit assay through the duration of treatment period, with the exception of rescue medicine usage (bisacodyl and loperamide) Clinically relevant changes in dietary, lifestyle, or exercise regimen within 30 days prior to Screening and for the duration of the study that may confound efficacy assessments in the clinical judgment of the Investigator (or designee)
Patient description: The patient is a 60-year-old woman admitted to the stroke department with a recent history of a second course of intravenous antibiotics for aspiration pneumonia. She is febrile and complained of abdominal pain and diarrhea (bowel movements eight times in 3 hours, large volumes of greenish, liquid stool each time). The patient's abdomen is generally tender and distend with hyperactive bowel sounds. She is febrile (38.4°C), tachycardic (113/min) and hypotensive (80/40 mmHg). The stool samples must were positive for Clostridium difficile toxin.

Clinical trial eligibility criteria: eligible ages (years): 18.0-65.0,  Irritable Bowel Syndrome Determined by participant medical history Diagnosed with IBS in the primary or secondary health care service IBS defined by the Rome IV Recurrent abdominal pain, on average at least 1 day per week during the previous 3 months, that is associated with two or more of the following: 1)Defecation, either increased pain or pain releif. 2)Change in stool frequency 3)Change in stool form (appearance) Moderate to severe IBS symptoms, as defined by a score of ≥175 on the IBS-SSS All participants >50 years Colonoscopy within the last 5 years prior to study entry including negative mucosal biopsy for microscopic colitis in participants subtyped as IBS-D No planned evaluations or examinations for bowel related complaints No presence of Malignant disease (excluding basalioma)
Patient description: The patient is a 60-year-old woman admitted to the stroke department with a recent history of a second course of intravenous antibiotics for aspiration pneumonia. She is febrile and complained of abdominal pain and diarrhea (bowel movements eight times in 3 hours, large volumes of greenish, liquid stool each time). The patient's abdomen is generally tender and distend with hyperactive bowel sounds. She is febrile (38.4°C), tachycardic (113/min) and hypotensive (80/40 mmHg). The stool samples must were positive for Clostridium difficile toxin.

Clinical trial eligibility criteria: eligible ages (years): 65.0-999.0,  Pneumonia Aspiration Pneumonia Pneumonia diagnosis: healthcare provider thinks it is more likely than not that patient has a pneumonia diagnosis Planned admission to UW hospital or willingness to come back for testing within 14 days Ability to provide consent or the presence of a legally authorized representative (LAR) who can consent on behalf of the patient  Prisoner Non-English speaking Planned admission to IMC or ICU or diagnosis of delirium Allergy to barium
Patient description: The patient is a 60-year-old woman admitted to the stroke department with a recent history of a second course of intravenous antibiotics for aspiration pneumonia. She is febrile and complained of abdominal pain and diarrhea (bowel movements eight times in 3 hours, large volumes of greenish, liquid stool each time). The patient's abdomen is generally tender and distend with hyperactive bowel sounds. She is febrile (38.4°C), tachycardic (113/min) and hypotensive (80/40 mmHg). The stool samples must were positive for Clostridium difficile toxin.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Clostridioides Difficile Infection Age more than or equal to 18 years Both genders Diarrhea defined as at least 3 episodes of unformed stools in the last 24hours according to the Bristol stool chart Presence of C.difficile in stool. This is defined as any stool sample positive for the presence of glutamate dehydrogenase (GDH) and for the presence of toxin A and/or B  • No apply